Thalidomide-NH-C8-NH2 hydrochloride is primarily utilized in research and development within the pharmaceutical industry, particularly in the study of targeted drug delivery systems. Its structure allows it to act as a linker or conjugate in the development of prodrugs, enabling the selective release of therapeutic agents at specific sites in the body. This compound is often explored in cancer therapy, where it can be used to enhance the efficacy of chemotherapeutic drugs while minimizing off-target effects. Additionally, it is investigated for its potential role in immunomodulation, particularly in conditions where regulating the immune response is critical, such as autoimmune diseases or certain cancers. Its application in these areas highlights its importance in advancing precision medicine approaches.